- AstraZeneca (NASDAQ:AZN) reports Phase II results from The CALAVI trials investigating BTK inhibitor Calquence (acalabrutinib) plus best supportive care (BSC) versus BSC alone in hospitalised patients with COVID-19 disease.
- Calquence did not meet the primary efficacy endpoint. The addition of Calquence to BSC did not increase the proportion of patients who remained alive and free of respiratory failure.
- No new safety signal was observed in the trials.
- The safety and tolerability profiles for Calquence in the CALAVI program were consistent with previous trials.
- The data will be presented in due course.
- https://seekingalpha.com/news/3635323-astrazenecas-calquence-flunks-mid-stage-covidminus-19-study
Thursday, November 12, 2020
AstraZeneca's Calquence flunks mid-stage COVID-19 study
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.